Abstract
To retrospectively evaluate the clinical utility of radiofrequencyablation (RFA) following transarterial injection of miriplatin-iodized oil suspension (MPT-RFA) for hepatocellular carcinoma treatment. We evaluated clinical outcomes of MPT-RFA for three or fewer hepatocellular carcinomas. Twenty-one patients with 30 tumors (maximum diameter: mean 1.4±0.4cm, range 0.7-2.2cm) received MPT-RFA. Nineteen patients (90.5%, 19/21) achieved complete ablation at the first RFA session. Two patients (9.5%, 2/21) required a second RFA session but achieved complete ablation. Primary and secondary technical success rates were 90.5 and 100%. There were no deaths related to the procedures performed. Grade 3 or 4 increases in the serum aspartate aminotransferase, alanine aminotransferase, and bilirubin levels were found in six patients (38.1%, 8/21). There were no liver infarctions. During the median follow-up period of 24.1months (mean±SD 24.7±6.9months, range 13.8-38.9months), the local tumor progression rate and overall survival rate at 2years was 5.0% (95% confidence interval 0.3-20.6%) and 86.7% (95% confidence interval 56.3-96.5%), respectively. The mean hospital stay was 8.4±3.1days (range 5-18days). MPT-RFA is a safe therapeutic option that initially provides therapeutic results.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call